Cogstate (ASX:CGS) reported total revenue of $26.9 million and executed $41.7 million of clinical trial sales contracts for the six months ended Dec. 31, 2025, according to a Thursday filing with the Australian bourse.
The company posted revenue of $23.9 million and executed net clinical trial sales contracts of $20.3 million for the six months ended Dec. 31,2024, an earlier filing showed.
The company now expects its fiscal 2026 earnings before interest, taxes, depreciation and amortization margin to be at the top end of the 20% to 23% range, the filing said.
Shares of the company rose past 7% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.